Refine
Year of publication
Document Type
- Preprint (719)
- Article (581)
- Conference Proceeding (5)
- Report (1)
- Working Paper (1)
Has Fulltext
- yes (1307)
Is part of the Bibliography
- no (1307)
Keywords
- Heavy Ion Experiments (21)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- SARS-CoV-2 (6)
- ALICE experiment (4)
- COVID-19 (4)
- COVID19-NMR (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- Solution NMR spectroscopy (4)
- 5′-UTR (3)
- ALICE (3)
- Heavy Ions (3)
- Heavy Quark Production (3)
- Jets and Jet Substructure (3)
- anal cancer (3)
- chemoradiotherapy (3)
- p53 (3)
- pp collisions (3)
- risk factors (3)
- Beauty production (2)
- Biochemistry (2)
- C-reactive protein (2)
- Charm physics (2)
- Collectivity (2)
- Correlation (2)
- Diffraction (2)
- Elastic scattering (2)
- Elliptic flow (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- HIV (2)
- Head and neck cancer (2)
- Heavy-ion collisions (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Patterns of care (2)
- Pb–Pb collisions (2)
- Postoperative radiochemotherapy (2)
- Precipitation inhibition (2)
- QCD (2)
- Quarkonium (2)
- RNA (2)
- Radiotherapy (2)
- Relativistic heavy-ion collisions (2)
- Shear viscosity (2)
- Single electrons (2)
- Supersaturation (2)
- Target validation (2)
- Treatment (2)
- albumin (2)
- biomarker (2)
- cervical cancer (2)
- chemotherapy (2)
- clinically important restrictions and symptoms (2)
- drug resistance (2)
- inflammation (2)
- local control (2)
- nutlin-3 (2)
- observational study (2)
- portal hypertension (2)
- rare disease (2)
- supersaturation (2)
- 19F (1)
- 5'-UTR (1)
- 5_SL4 (1)
- 900 GeV (1)
- ACLF (1)
- ADHD (1)
- AIDS (1)
- ALICE detector (1)
- Adolescents (1)
- Advanced stage (1)
- Anal cancer (1)
- Anti-kaon–nucleon physics (1)
- Anti-nuclei (1)
- Archaeogeophysics (1)
- Atomic and molecular interactions with photons (1)
- Attention-Deficit/Hyperactivity Disorder (ADHD) (1)
- Azores Archipelago (1)
- B-slope (1)
- Biochemistry and chemical biology (1)
- Biodiversity (1)
- Bioenabling formulations (1)
- Biomarker (1)
- Blood sample handling (1)
- Boosted Jets (1)
- CAR (1)
- CD8 (1)
- CD8+ tumor infiltrating lymphocytes (1)
- CNS toxicity (1)
- COVID (1)
- COVID‐19 (1)
- CRT (1)
- CXCR4 (1)
- Cancer genomics (1)
- Centrality Class (1)
- Centrality Selection (1)
- Charge fluctuations (1)
- Charged-particle multiplicity (1)
- Charm quark spatial diffusion coefficient (1)
- Chemical composition (1)
- Chemical physics (1)
- Chemoradiotherapy (1)
- Coalescence (1)
- Cold nuclear matter effects (1)
- Collective Flow, (1)
- Comparative genomics (1)
- Comparison with QCD (1)
- Complicated stage (1)
- Conduct disorder (1)
- Conformational trapping (1)
- Contingent Negative Variation, CNV (1)
- Continuous Performance Test, CPT (1)
- Costs (1)
- Covid19-nmr (1)
- Critical point (1)
- Cue-P3 (1)
- DKTK-ROG (1)
- DNA-PAINT (1)
- Data management (1)
- Data sharing (1)
- Demolition emissions (1)
- Depression (1)
- Deuteron production (1)
- Di-hadron correlations (1)
- Direct oral anticoagulation (1)
- Direct reactions (1)
- Disease Activity (1)
- E. colo (1)
- EP300 (1)
- EWSR1 (1)
- Early Rheumatoid Arthritis (1)
- Ecosystems (1)
- Electron-pion identification (1)
- Electronic structure of atoms and molecules (1)
- Electroweak interaction (1)
- Emotion regulation (1)
- Endocannabinoids (1)
- Enthalpy (1)
- Environment (1)
- Epilepsy (1)
- Ethics Committees/Consultation (1)
- European distribution (1)
- Event related potentials (1)
- Evolution (1)
- FBS (1)
- FOXO1 (1)
- Family Physician (1)
- Females (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- First-line regimen (1)
- Forschung (1)
- Full waveform (1)
- Fungi (1)
- G protein-coupled receptor (GPCR) (1)
- Gene expression profiling (1)
- Gene fusion (1)
- Glioblastoma survival (1)
- Groomed jet radius (1)
- HBT (1)
- HNO (1)
- HNSCC (1)
- HPV (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Hard Scattering (1)
- Health information (1)
- Health-seeking behaviour (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-Ion Collision (1)
- Heavy-flavor decay electron (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Helpline (1)
- High-throughput screening (1)
- Higher moments (1)
- HoLEP (1)
- Holmium laser enucleation (1)
- Hsp70 (1)
- ICON model (1)
- IHC (1)
- Imrt (1)
- In vitro selection (1)
- Incidental prostate cancer (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Interference fragmentation function (1)
- Interpretation (1)
- Invariant Mass Distribution (1)
- Inversion (1)
- Ionisation energy loss (1)
- J/ψ suppression (1)
- Jet Physics (1)
- Jet Substructure (1)
- Jet substructure (1)
- KCGS (1)
- Kaonic nuclei (1)
- Ki-67/MIB1 (1)
- LEOSS (1)
- Lehre (1)
- Loimia (1)
- Low energy QCD (1)
- Low-molecular-weight heparin (1)
- Lymphocytes (1)
- Lymphoid tissues (1)
- MDM2 (1)
- MRI (1)
- Machine learning (1)
- Massive Online Open Course (1)
- Material budget (1)
- Mechanistic (1)
- Medication Appropriateness Index (1)
- Medicinal chemistry (1)
- Membrane protein (1)
- Mesoporous silica (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Molecular diagnostics (1)
- Molecular modelling (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multiple parton interactions (1)
- Myocarditis (1)
- NK cells (1)
- NMR spectroscopy (1)
- NSCLC (1)
- Nanobody (1)
- Nek1 (1)
- Neural network (1)
- Neuroepithelial tumor (1)
- Neurofeedback (1)
- Nuclear modification factor (1)
- Nuclear reactions (1)
- Nuclear structure & decays (1)
- Nucleon induced nuclear reactions (1)
- ORL (1)
- Observation (1)
- Oncology (1)
- Oppositional defiant disorder (1)
- Otorhinolaryngology (1)
- Outcomes research (1)
- PCV (1)
- PD-L1 (1)
- PLAGL1 (1)
- PM10 (1)
- PYTHIA (1)
- Partial wave analysis (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Phage display (1)
- Pharmacology (1)
- Plant symbiosis (1)
- Plasma (1)
- Pneumocystis jirovecii (1)
- Pneumonia (1)
- Point of care (1)
- Polo-like kinase 3 (1)
- Pre-analytics (1)
- Predictive model (1)
- Primary Care Health Centre (1)
- Production Cross Section (1)
- Prognostic (1)
- Properties of Hadrons (1)
- Prostate cancer (1)
- Proteins (1)
- Proton-proton collisions (1)
- Proton–proton (1)
- Proton–proton collisions (1)
- Pulmonary embolism (1)
- QGP (1)
- Quality of life (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- RHIC (1)
- RITA (1)
- RNA Biology (1)
- RNA genome (1)
- RNASolution-state NMR (1)
- Randomised controlled trial (1)
- Randomized Controlled Trial (1)
- Rapidity Range (1)
- Rare diseases (1)
- Relativistic heavy ion physics (1)
- Research (1)
- Research Ethics (1)
- Residency (1)
- Residential care (1)
- Resolution Parameter (1)
- Response control (1)
- Rheumatoid Arthritis (1)
- Ribosome display (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SCCHN (1)
- SDF-1 (1)
- SEDDS (1)
- SL1 (1)
- SL5a (1)
- SL5b (1)
- SL5b + c (1)
- SL5c (1)
- SMAD (1)
- SMEDDS (1)
- SNEDDS (1)
- SPSS (1)
- Salivary gland cancer (1)
- Salivary gland carcinoma (1)
- Scientific Research (1)
- Screening (1)
- Seizure (1)
- Serum (1)
- Shell model (1)
- Single muons (1)
- Size distribution (1)
- Skills training (1)
- Slow Cortical Potentials, SCP (1)
- Small molecules (1)
- Social Control of Human Experimentation (1)
- Social Control of Science/Technology (1)
- Socio-ecology (1)
- SoftDrop (1)
- Solid dispersion (1)
- Sonography (1)
- Spanish National Health System (1)
- Specialist training (1)
- Spectroscopic factors & electromagnetic moments (1)
- Splitting function (1)
- Ste2p (1)
- Stereotactic ablative body radiotherapy (1)
- Structural biology and molecular biophysics (1)
- Supratentorial (1)
- Surgery (1)
- Survey (1)
- Sustained attention (1)
- Systematic Uncertainty (1)
- Systemic therapy (1)
- TGFβ (1)
- TR (1)
- TTFields (1)
- TUR-P (1)
- Teaching (1)
- Techniques and instrumentation (1)
- Telemedicine (1)
- Therapeutic anticoagulation (1)
- Thermal model (1)
- Time Projection Chamber (1)
- Tomography (1)
- Tools and ressources (1)
- Topology (1)
- Tracking (1)
- Transition radiation detector (1)
- Transurethral resection of the prostate (1)
- Transverse momentum (1)
- Transversity (1)
- Treatment modification (1)
- Trigger (1)
- Ultrafine particles (1)
- University hospitals (1)
- Universitätskliniken (1)
- Urban aerosol (1)
- Vaccination (1)
- Vector Boson Production (1)
- Weiterbildung (1)
- X-rays (1)
- Xenon-based gas mixture (1)
- accident (1)
- acoustic radiation force impulse (1)
- acute decompensation (1)
- acute-on-chronic liver failure (1)
- aggression (1)
- aging (1)
- algal evolution (1)
- amorphous stability (1)
- anal carcinoma (1)
- antiviral therapy (1)
- archeological modeling (1)
- artifacts (1)
- attention-deficit/hyperactivity disorder (ADHD) (1)
- biogeographic legaciese (1)
- brain cancer (1)
- cART (1)
- cBioPortal (1)
- cancer (1)
- cancer-specific survival (1)
- caspase 8 (1)
- caspase-8 (1)
- chemogenomic set (1)
- chemoresistance (1)
- chromalveolate (1)
- chronic hepatitis C (1)
- cirrhosis (1)
- clinical (1)
- clinical practice (1)
- colorectal cancer (1)
- comorbidities (1)
- complex plastid (1)
- computational biology (1)
- computed tomography (1)
- computer-assisted (1)
- congenital duodenal obstruction (1)
- consensus (1)
- corneas (1)
- corticosteroids (1)
- critically ill patients (1)
- crystal structure determination (1)
- dE/dx (1)
- data quality (1)
- decision making (1)
- decision support systems (1)
- deep neural network models (1)
- deswelling (1)
- detector (1)
- dexamethasone (1)
- diffuse low-grade glioma (1)
- diffusion-weighted magnetic resonance imaging (1)
- direct-acting antiviral (DAA) treatment (1)
- disease-free survival (1)
- drug discovery (1)
- druggable genome (1)
- ectosomes (1)
- electroencephalography (EEG) (1)
- eltrombopag (1)
- emiliania huxleyi (1)
- epilepsy (1)
- excitation (1)
- exosomes (1)
- experimental results (1)
- extracellular vesicles (1)
- fMRI (1)
- fMRI/EEG (1)
- fluorine (1)
- forest classification (1)
- forest functional similarity (1)
- fractionation (1)
- fragment screening (1)
- fragment-based screening (1)
- freshwater ecosystems (1)
- gastrointestinal stromal tumours (1)
- gene signature (1)
- glass forming ability (1)
- glioblastoma survival (1)
- glioma (1)
- global change (1)
- guidelines (1)
- habitat destruction (1)
- head and neck squamous cell carcinoma (1)
- health-related quality of life (1)
- health-relatedquality of life (1)
- heavy ion experiments (1)
- hepatic encephalopathy (1)
- highly-charged ions (1)
- hotmelt extrusion (1)
- hotspot loci (1)
- human (1)
- human cytomegalovirus (1)
- human–environment interaction (1)
- hydrate (1)
- hypothesis (1)
- immune microenvironment (1)
- immunotherapy (1)
- in silico tools (1)
- injury (1)
- insect abundance (1)
- interscalene brachial plexus block (1)
- intraspecific morphological variability (1)
- iron chelation (1)
- keratoplasty (1)
- kinase inhibitor (1)
- land use (1)
- lasso regression (1)
- leukocytosis (1)
- leukopenia (1)
- lipid based formulation (1)
- lipid suspension (1)
- liver (1)
- liver cirrhosis (1)
- local anesthetic (1)
- lockdown (1)
- logistic models (1)
- long-term research (1)
- lung cancer (1)
- mRNA and protein expression (1)
- machine learning (1)
- maternal care (1)
- membrane protein (1)
- merkel cell carcinoma (1)
- mesoporous silica (1)
- metabolic syndromes (1)
- microdeletions (1)
- microkeratome (1)
- microparticles (1)
- microvesicles (1)
- minimal information requirements (1)
- molecular tumor board (1)
- multicenter study (1)
- multiplexed immunofluorescence (1)
- multivariate pattern analysis (1)
- myeloperoxidase (1)
- neoadjuvant chemoradiotherapy (1)
- neoplasms (1)
- neurodegeneration (1)
- neurodevelopmental (1)
- neurological outcome (1)
- neuroscience (1)
- neutrophils (1)
- nomogram (1)
- nuclear magnetic resonance (NMR) (1)
- open science (1)
- oral cavity cancer (1)
- organic pigment (1)
- organic thin films (1)
- outcome (1)
- ovarian cancer (1)
- overall survival (1)
- p+p collisions (1)
- p16 (1)
- p53 activator (1)
- paleoclimate modeling (1)
- paleoenvironment modeling (1)
- paleoenvironment reconstruction (1)
- parameterization development (1)
- pediatric intensive care (1)
- pediatric surgery (1)
- peri-implantitis (1)
- phenotypic screening (1)
- phylogenetic community distance (1)
- plastid protein import (1)
- polo-like kinase 1 (1)
- polo-like kinase 3 (1)
- polymers (1)
- polyomavirus (MCPyV) (1)
- portosystemic shunt (1)
- postnatal care (1)
- postoperative radiochemotherapy (1)
- postoperative radiotherapy (1)
- ppK − (1)
- precipitation inhibitor (1)
- precision medicine (1)
- predictive (1)
- predictive biomarker (1)
- prenatal diagnostic (1)
- prognosis (1)
- prognostic (1)
- prognostic biomarker (1)
- prognostic marker (1)
- propensity score matching (1)
- protein folding (1)
- protein kinase (1)
- proteins (1)
- pulmonary embolism (1)
- quark gluon plasma (1)
- radiation (1)
- radioimmunotherpay (1)
- radiosensitization (1)
- real-world structure (1)
- recurrence pattern (1)
- relativistic collisions (1)
- reproducibility (1)
- requirements analysis (1)
- resilience (1)
- retrospective trial (1)
- rigor (1)
- sarcoma (1)
- sarcopenia (1)
- scene representation (1)
- secondary endosymbiosis (1)
- selenolates (1)
- self-assembled monolayers (1)
- short molecular distance (1)
- single-column mode (1)
- small molecules (1)
- solvate (1)
- spectra (1)
- spontaneous portosystemic shunt (1)
- standardization (1)
- storage rings (1)
- structural biology (1)
- super-SMEDDS (1)
- super-SNEDDS (1)
- supersaturating drug delivery systems (1)
- survival (1)
- temozolomide (1)
- therapeutic anticoagulation (1)
- thiolates (1)
- threats (1)
- thrombopenia (1)
- thrombopietin receptor agonist (1)
- toxic hemisphere syndrome (1)
- toxicity (1)
- transient elastography (1)
- translational investigation (1)
- trauma (1)
- triptycene (1)
- tropical forests (1)
- tumor microenvironment (1)
- tumor-infiltrating-lymphocytes (1)
- tyrosine kinase inhibitors (1)
- understudied kinase (1)
- validation (1)
- venetoclax (1)
- ventral striatum (1)
- visual perception (1)
- xenograft (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1129)
- Frankfurt Institute for Advanced Studies (FIAS) (992)
- Informatik (921)
- Medizin (88)
- Geowissenschaften (16)
- Biochemie, Chemie und Pharmazie (14)
- Biowissenschaften (11)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (8)
- Biochemie und Chemie (7)
- Institut für Ökologie, Evolution und Diversität (5)
Tumor cells frequently overexpress heat shock protein 70 (Hsp70) and present it on their cell surface, where it can be recognized by pre‐activated NK cells. In our retrospective study the expression of Hsp70 was determined in relation to tumor‐infiltrating CD56+ NK cells in formalin‐fixed paraffin embedded (FFPE) tumor specimens of patients with SCCHN (N = 145) as potential indicators for survival and disease recurrence. All patients received radical surgery and postoperative cisplatin‐based radiochemotherapy (RCT). In general, Hsp70 expression was stronger, but with variable intensities, in tumor compared to normal tissues. Patients with high Hsp70 expressing tumors (scores 3–4) showed significantly decreased overall survival (OS; p = 0.008), local progression‐free survival (LPFS; p = 0.034) and distant metastases‐free survival (DMFS; p = 0.044), compared to those with low Hsp70 expression (scores 0–2), which remained significant after adjustment for relevant prognostic variables. The adverse prognostic value of a high Hsp70 expression for OS was also observed in patient cohorts with p16‐ (p = 0.001), p53‐ (p = 0.0003) and HPV16 DNA‐negative (p = 0.001) tumors. The absence or low numbers of tumor‐infiltrating CD56+ NK cells also correlated with significantly decreased OS (p = 0.0001), LPFS (p = 0.0009) and DMFS (p = 0.0001). A high Hsp70 expression and low numbers of tumor‐infiltrating NK cells have the highest negative predictive value (p = 0.00004). In summary, a strong Hsp70 expression and low numbers of tumor‐infiltrating NK cells correlate with unfavorable outcome following surgery and RCT in patients with SCCHN, and thus serve as negative prognostic markers.
Background: The approval of everolimus (EVE) for the treatment of angiomyolipoma (2013), subependymal giant cell astrocytoma (2013) and drug-refractory epilepsy (2017) in patients with tuberous sclerosis complex (TSC) represents the first disease-modifying treatment option available for this rare and complex genetic disorder. Objective: The objective of this study was to analyse the use, efficacy, tolerability and treatment retention of EVE in patients with TSC in Germany from the patient’s perspective. Methods: A structured cross-age survey was conducted at 26 specialised TSC centres in Germany and by the German TSC patient advocacy group between February and July 2019, enrolling children, adolescents and adult patients with TSC. Results: Of 365 participants, 36.7% (n = 134) reported the current or past intake of EVE, including 31.5% (n = 115) who were taking EVE at study entry. The mean EVE dosage was 6.1 ± 2.9 mg/m2 (median: 5.6 mg/m2, range 2.0–15.1 mg/m2) in children and adolescents and 4 ± 2.1 mg/m2 (median: 3.7 mg/m2, range 0.8–10.1 mg/m2) in adult patients. An early diagnosis of TSC, the presence of angiomyolipoma, drug-refractory epilepsy, neuropsychiatric manifestations, subependymal giant cell astrocytoma, cardiac rhabdomyoma and overall multi-organ involvement were associated with the use of EVE as a disease-modifying treatment. The reported efficacy was 64.0% for angiomyolipoma (75% in adult patients), 66.2% for drug-refractory epilepsy, and 54.4% for subependymal giant cell astrocytoma. The overall retention rate for EVE was 85.8%. The retention rates after 12 months of EVE therapy were higher among adults (93.7%) than among children and adolescents (88.7%; 90.5% vs 77.4% after 24 months; 87.3% vs 77.4% after 36 months). Tolerability was acceptable, with 70.9% of patients overall reporting adverse events, including stomatitis (47.0%), acne-like rash (7.7%), increased susceptibility to common infections and lymphoedema (each 6.0%), which were the most frequently reported symptoms. With a total score of 41.7 compared with 36.8 among patients not taking EVE, patients currently being treated with EVE showed an increased Liverpool Adverse Event Profile. Noticeable deviations in the sub-items ‘tiredness’, ‘skin problems’ and ‘mouth/gum problems’, which are likely related to EVE-typical adverse effects, were more frequently reported among patients taking EVE. Conclusions: From the patients’ perspective, EVE is an effective and relatively well-tolerated disease-modifying treatment option for children, adolescents and adults with TSC, associated with a high long-term retention rate that can be individually considered for each patient. Everolimus therapy should ideally be supervised by a centre experienced in the use of mechanistic target of rapamycin inhibitors, and adverse effects should be monitored on a regular basis.
Introduction: Dravet syndrome (DS) is a rare developmental and epileptic encephalopathy. This study estimated cost, cost-driving factors and quality of life (QoL) in patients with Dravet syndrome and their caregivers in a prospective, multicenter study in Germany.
Methods: A validated 3–12-month retrospective questionnaire and a prospective 3-month diary assessing clinical characteristics, QoL, and direct, indirect and out-of-pocket (OOP) costs were administered to caregivers of patients with DS throughout Germany.
Results: Caregivers of 93 patients (mean age 10.1 years, ±7.1, range 15 months–33.7 years) submitted questionnaires and 77 prospective diaries. The majority of patients (95%) experienced at least one seizure during the previous 12 months and 77% a status epilepticus (SE) at least once in their lives. Over 70% of patients had behavioural problems and delayed speech development and over 80% attention deficit symptoms and disturbance of motor skills and movement coordination. Patient QoL was lower than in the general population and 45% of caregivers had some form of depressive symptoms. Direct health care costs per three months were a mean of €6,043 ± €5,825 (median €4054, CI €4935-€7350) per patient. Inpatient costs formed the single most important cost category (28%, €1,702 ± €4,315), followed by care grade benefits (19%, €1,130 ± €805), anti-epileptic drug (AED) costs (15%, €892 ± €1,017) and ancillary treatments (9%, €559 ± €503). Total indirect costs were €4,399 ±€ 4,989 (median €0, CI €3466-€5551) in mothers and €391 ± €1,352 (median €0, CI €195-€841) in fathers. In univariate analysis seizure frequency, experience of SE, nursing care level and severe additional symptoms were found to be associated with total direct healthcare costs. Severe additional symptoms was the single independently significant explanatory factor in a multivariate analysis.
Conclusions: This study over a period up to 15 months revealed substantial direct and indirect healthcare costs of DS in Germany and highlights the relatively low patient and caregiver QoL compared with the general population.
Background Microdeletions are known to confer risk to epilepsy, particularly at genomic rearrangement “hotspot” loci. However, deciphering their role outside hotspots and risk assessment by epilepsy sub-type has not been conducted.
Methods We assessed the burden, frequency and genomic content of rare, large microdeletions found in a previously published cohort of 1,366 patients with Genetic Generalized Epilepsy (GGE) plus two sets of additional unpublished genome-wide microdeletions found in 281 Rolandic Epilepsy (RE) and 807 Adult Focal Epilepsy (AFE) patients, totaling 2,454 cases. These microdeletion sets were assessed in a combined analysis and in sub-type specific approaches against 6,746 ethnically matched controls.
Results When hotspots are considered, we detected an enrichment of microdeletions in the combined epilepsy analysis (adjusted-P= 2.00×10-7; OR = 1.89; 95%-CI: 1.51-2.35), where the implicated microdeletions overlapped with rarely deleted genes and those involved in neurodevelopmental processes. Sub-type specific analyses showed that hotspot deletions in the GGE subgroup contribute most of the signal (adjusted-P = 1.22×10-12; OR = 7.45; 95%-CI = 4.20-11.97). Outside hotspot loci, microdeletions were enriched in the GGE cohort for neurodevelopmental genes (adjusted-P = 4.78×10-3; OR = 2.30; 95%-CI = 1.42-3.70), whereas no additional signal was observed for RE and AFE. Still, gene content analysis was able to identify known (NRXN1, RBFOX1 and PCDH7) and novel (LOC102723362) candidate genes affected in more than one epilepsy sub-type but not in controls.
Conclusions Our results show a heterogeneous effect of recurrent and non-recurrent microdeletions as part of the genetic architecture of GGE and a minor to negligible contribution in the etiology of RE and AFE.
Purpose: Seizures pose a significant burden in patients with primary and secondary brain tumors during the end-of-life period. A wide range of 6 to 56% of clinically observed epileptic seizures at the end of life has been reported. We aimed to analyse the incidence of epileptic seizures at the end of life in brain tumor patients more accurately using not only clinical but also electrophysiological findings.
Methods: This retrospective, single center study included brain tumor patients who died during the stay on the ward or within 7 days after discharge between 01/2015 and 08/2020. Clinical observation of seizures derived from the original medical records and EEG findings (within 45 days prior to death) were analyzed to determine the incidence of seizures in that period.
Results: Of the 68 eligible patients, 50 patients (73.5%) suffered from seizures within 45 days prior to death, of which n = 24 had a status epilepticus. The diagnosis of seizures/ status epilepticus was determined either by the presentation of clinical signs in 45 patients and if not, by the detection of a (possible) non-convulsive status epilepticus in the EEG of five patients.
Conclusion: In the presence of neurologically trained staff and with the frequent use of routine EEG, we were able to identify seizures and to distinguish status epilepticus from encephalopathy/ hypoactive delirium. We detected a higher incidence of seizures and status epilepticus at the end of life in neurooncological patients than previously reported.
Background: To study neoadjuvant chemoradiotherapy (nCRT) and potential predictive factors for response in locally advanced oral cavity cancer (LA-OCC).
Methods: The INVERT trial is an ongoing single-center, prospective phase 2, proof-of-principle trial. Operable patients with stage III-IVA squamous cell carcinomas of the oral cavity were eligible and received nCRT consisting of 60 Gy with concomitant cisplatin and 5-fluorouracil. Surgery was scheduled 6-8 weeks after completion of nCRT. Explorative, multiplex immunohistochemistry (IHC) was performed on pretreatment tumor specimen, and diffusion-weighted magnetic resonance imaging (DW-MRI) was conducted prior to, during nCRT (day 15), and before surgery to identify potential predictive biomarkers and imaging features. Primary endpoint was the pathological complete response (pCR) rate.
Results: Seventeen patients with stage IVA OCC were included in this interim analysis. All patients completed nCRT. One patient died from pneumonia 10 weeks after nCRT before surgery. Complete tumor resection (R0) was achieved in 16/17 patients, of whom 7 (41%, 95% CI: 18-67%) showed pCR. According to the Clavien-Dindo classification, grade 3a and 3b complications were found in 4 (25%) and 5 (31%) patients, respectively; grade 4-5 complications did not occur. Increased changes in the apparent diffusion coefficient signal intensities between MRI at day 15 of nCRT and before surgery were associated with better response (p=0.022). Higher abundances of programmed cell death protein 1 (PD1) positive cytotoxic T-cells (p=0.012), PD1+ macrophages (p=0.046), and cancer-associated fibroblasts (CAFs, p=0.036) were associated with incomplete response to nCRT.
Conclusion: nCRT for LA-OCC followed by radical surgery is feasible and shows high response rates. Larger patient cohorts from randomized trials are needed to further investigate nCRT and predictive biomarkers such as changes in DW-MRI signal intensities, tumor infiltrating immune cells, and CAFs.
Children’s and adolescents’ lives drastically changed during COVID lockdowns worldwide. To compare accident- and injury-related admissions to pediatric intensive care units (PICU) during the first German COVID lockdown with previous years, we conducted a retrospective multicenter study among 37 PICUs (21.5% of German PICU capacities). A total of 1444 admissions after accidents or injuries during the first lockdown period and matched periods of 2017–2019 were reported and standardized morbidity ratios (SMR) were calculated. Total PICU admissions due to accidents/injuries declined from an average of 366 to 346 (SMR 0.95 (CI 0.85–1.05)). Admissions with trauma increased from 196 to 212 (1.07 (0.93–1.23). Traffic accidents and school/kindergarten accidents decreased (0.77 (0.57–1.02 and 0.26 (0.05–0.75)), whereas household and leisure accidents increased (1.33 (1.06–1.66) and 1.34 (1.06–1.67)). Less neurosurgeries and more visceral surgeries were performed (0.69 (0.38–1.16) and 2.09 (1.19–3.39)). Non-accidental non-suicidal injuries declined (0.73 (0.42–1.17)). Suicide attempts increased in adolescent boys (1.38 (0.51–3.02)), but decreased in adolescent girls (0.56 (0.32–0.79)). In summary, changed trauma mechanisms entailed different surgeries compared to previous years. We found no evidence for an increase in child abuse cases requiring intensive care. The increase in suicide attempts among boys demands investigation.